New Strategies, Targets in Triple-Negative Breast Cancer

Video

This video with Stacy Moulder, MD, highlights efforts to identify various subtypes and molecular targets in triple-negative breast cancer, which could lead to treatment options with already approved agents.

In this video, Stacy Moulder, MD, of MD Anderson Cancer Center, highlights efforts to identify various subtypes and molecular targets in triple-negative breast cancer, an often difficult-to-treat disease, which could potentially lead to treatment options already approved by the US Food and Drug Administration.

Dr. Moulder also discusses the challenge in finding patients with triple-negative disease that will have durable responses to chemotherapy, and the need for better molecular diagnostic assays to identify those patients who will be resistant to cytotoxic agents.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
4 experts in this video
4 experts in this video
Related Content